logo
Twitter
Discord
Email
logo
Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

NASDAQ•TARA
CEO: Mr. Jesse Shefferman
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-10-22
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Contact Information
345 Park Avenue South, 3rd Floor, New York, NY, 10010, United States
646-844-0337
www.protaratx.com
Market Cap
$193.33M
P/E (TTM)
-4.0
38.2
Dividend Yield
--
52W High
$7.82
52W Low
$2.77
52W Range
44%
Rank68Top 98.2%
1.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.31-38.00%
4-Quarter Trend

FCF

-$12.46M+47.55%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong TARA-002 Clinical Response BCG-Unresponsive dataset showed 100% CR rate at six months; BCG-Naïve cohort achieved 63% CR rate at six months.
Adequate Liquidity Position Unrestricted cash and marketable debt securities totaled $133.6M as of September 30, 2025; sufficient for twelve months.
Increased Investment Income Other income (expense), net increased $2.3M for nine months, driven by higher returns on invested cash balances.
Common Shares Outstanding Common shares outstanding reached 38.59M as of September 30, 2025, up from 35.04M at year-end 2024.

Risk Factors

Widening Net Operating Loss Nine-month net loss widened to $(40.1)M in 2025 from $(31.8)M in 2024, reflecting increased R&D spending.
R&D Expenses Significantly Higher Total R&D expenses rose $7.3M (up 32.9%) for nine months, driven by TARA-002 and IV Choline Chloride startup costs.
Higher Cash Used Operating Cash used in operating activities increased $12.9M to $(39.4)M for nine months due to higher net loss incurred.
Need for Future Capital Company has no near-term revenues and requires substantial additional capital to realize management's drug development plans.

Outlook

Advance IV Choline Chloride Plan to dose first patient in registrational THRIVE-3 Phase 3 clinical trial for IV Choline Chloride by end of 2025.
Upcoming TARA-002 Data Expect interim analysis for Cohort B (BCG-Unresponsive) in Q1 2026; update on BCG-Naïve program in Q4 2025.
Focus on Combination Therapies Intend to evaluate TARA-002 combination therapy options for NMIBC and explore other maxillofacial cyst applications.
Unrecognized Stock Compensation Approximately $6.6M in unrecognized stock-based compensation for unvested options expected to be recognized over 2.60 years.

Peer Comparison

Revenue (TTM)

Genfit S.A.GNFT
$126.71M
+9.8%
Codexis, Inc.CDXS
$52.93M
-17.9%
Invivyd, Inc.IVVD
$50.04M
+243.0%

Gross Margin (Latest Quarter)

Genfit S.A.GNFT
100.0%
+0.0pp
Assembly Biosciences, Inc.ASMB
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+4.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IVVD$325.19M-7.0-93.0%1.9%
GNFT$312.23M-6.8-63.7%64.1%
ASMB$252.91M-5.8-59.0%1.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 4, 2026
|
EPS:-$0.36
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.31-38.0%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.35-22.2%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.29-70.1%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.17+39.2%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.50-42.5%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.45-55.0%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.97+31.1%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.57+39.1%
    N/A